COX-2 in liver,from regeneration to hepatocarcinogenesis:What we have learned from animal models?

被引:12
|
作者
Paloma Martín-Sanz [1 ,2 ]
Rafael Mayoral [1 ,2 ]
Marta Casado [1 ,3 ]
Lisardo Boscá [1 ,2 ]
机构
[1] Biomedical Network Center for the Study of Hepatic and Digestive Diseases(CIBERehd)
[2] Department of Metabolism and Cell Signaling,Institute of Biomedical Research "Alberto Sols"(CSIC-UAM)
[3] Department of Pathology and Molecular and Cellular Therapy,Institute of Biomedicine of Valencia(IBV-CSIC)
关键词
Cyclooxygenase; 2; Prostaglandins; Liver diseases; Apoptosis; Inflammation; Animal models;
D O I
暂无
中图分类号
R735.7 [肝肿瘤];
学科分类号
100214 ;
摘要
The use of animals lacking genes or expressing genes under the control of cell-specific promoters has signifi cantly increased our knowledge of the genetic and molecular basis of physiopathology,allowing testing of functional hypotheses and validation of biochemical and pharmacologic approaches in order to understand cell function.However,with unexpected frequency,gene knockout animals and,more commonly,animal models of transgenesis give experimental support to even opposite conclusions on gene function.Here we summarize what we learned on the role of cyclooxygenase 2(COX-2) in liver and revise the results obtained in 3 independent models of mice expressing a COX-2 transgene specifi cally in the hepatocyte.Upon challenge with pro-inflammatory stimuli,the animals behave very differently,some transgenic models having a protective effect but others enhancing the injury.In addition,one transgene exerts differential effects on normal liver physiology depending on the transgenic animal model used.
引用
收藏
页码:1430 / 1435
页数:6
相关论文
共 50 条
  • [41] The Role of CCN1 in Esophageal Adenocarcinoma: What We Have Learned From the Lab
    Chang, Zhiheng
    Dang, Tong
    Meng, Xianmei
    Chai, Jianyuan
    CANCER CONTROL, 2022, 29
  • [42] The Role of CCN1 in Esophageal Adenocarcinoma: What We Have Learned From the Lab
    Chang, Zhiheng
    Dang, Tong
    Meng, Xianmei
    Chai, Jianyuan
    CANCER CONTROL, 2022, 29
  • [43] The Role of CCN1 in Esophageal Adenocarcinoma: What We Have Learned From the Lab
    Chang, Zhiheng
    Dang, Tong
    Meng, Xianmei
    Chai, Jianyuan
    CANCER CONTROL, 2022, 29
  • [44] Animal Models for Dysphagia Studies: What Have We Learnt So Far
    Rebecca Z. German
    A. W. Crompton
    Francois D. H. Gould
    Allan J. Thexton
    Dysphagia, 2017, 32 : 73 - 77
  • [45] Models to evaluate the pulmonary toxicity of desert dust and what we have learned from them so far: a mini-review
    Bredeck, Gerrit
    Schins, Roel P. F.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2025,
  • [46] From prostaglandin replacement to specific COX-2 inhibition: A critical appraisal
    Kremer, J
    JOURNAL OF RHEUMATOLOGY, 2000, 27 : 9 - 12
  • [47] Non-Alcoholic Steatohepatitis: What Can We Learn from Animal Models?
    Almonacid-Urrego, C. C.
    Sanchez-Campos, S.
    Tunon, M. J.
    Gonzalez-Gallego, J.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (09) : 1389 - 1404
  • [48] Role of Bcl-2 family members on apoptosis: what we have learned from knock-out mice
    Roset, Ramon
    Ortet, Laura
    Gil-Gomez, Gabriel
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2007, 12 : 4722 - 4730
  • [49] The SARS-CoV-2 pandemic and asthma: What we have learned and what is still unknown
    Mcphee, Christa
    Yevdokimova, Kateryna
    Rogers, Linda
    Kraft, Monica
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 152 (06) : 1376 - 1381
  • [50] Neurotoxicity, General Anesthesia, and the Developing Brain: What have We Learned from the Human Studies so Far?
    Hansen T.G.
    Current Anesthesiology Reports, 2013, 3 (3) : 175 - 183